American journal of rhinology & allergy
-
Am J Rhinol Allergy · Mar 2014
Randomized Controlled TrialEfficacy and safety of sublingual immunotherapy in children aged 3-13 years with allergic rhinitis.
Sublingual immunotherapy (SLIT) is recommended for allergic diseases. However, clinical studies containing evidence-based data of this treatment in young children, which is rarely reported in the literature, are needed. This study was designed to assess the efficacy and safety of SLIT in children, including very young children. ⋯ SLIT is effective and well-tolerated in children with allergic rhinitis 3-13 years old.